Last Updated: April 30, 2026

Profile for Serbia Patent: 62435


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Serbia Patent: 62435

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Apr 20, 2035 Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam
⤷  Start Trial Apr 20, 2035 Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam
⤷  Start Trial Apr 20, 2035 Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam
⤷  Start Trial Apr 20, 2035 Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

What Is the Patent Scope and Claims for Serbia Drug Patent RS62435, and How Does It Sit in the Patent Landscape?

Last updated: April 23, 2026

What is RS62435 (and what does it cover)?

RS62435 is a Serbian patent tied to pharmaceutical subject matter and is identified in the Serbian patent publication record as RS 62435. The patent family context, claim scope, and landscape positioning depend on the patent’s independent claim structure (composition vs method vs use), and the country-by-country validation across filings in Europe.

However, no usable claim text, bibliographic fields, assignee, priority data, or legal status for “RS62435” is present in the provided material in this chat. Without the actual RS62435 record (publication number, title, assignee, priority date, claim set, and status), a complete and accurate scope-and-claims analysis cannot be produced.

What do the claims likely look like (composition vs method vs use)?

A reliable claim-scope breakdown requires the exact wording of RS62435’s independent claims and the claim dependencies. Typical pharma claim architectures include:

  • Composition claims (drug substance, salts, solvates, polymorphs, formulations)
  • Method of treatment claims (use of a compound for a therapeutic indication)
  • Use claims (second medical use)
  • Process claims (manufacturing steps)

But producing an accurate mapping of RS62435 to these buckets requires the literal claim text.

What is the effective patent landscape impact in Serbia?

To determine Serbia landscape impact, the analysis must establish:

  • Whether RS62435 is a composition-of-matter patent, use patent, or formulation patent
  • Whether it has active validity in Serbia (maintenance, revocation, lapse)
  • Whether there are overlapping or blocking earlier filings (priority chain)
  • Whether later filings in the same family (e.g., polymorph, salt, formulation, dosing regimen) exist and are enforceable in Serbia

This cannot be done without the Serbian record and its family chain identifiers.


Evidence-based scope and claims analysis

Claim map (requires RS62435 claim text)

A claim map must cite:

  • Claim number
  • Claim category (independent/dependent)
  • Elements (compound identity, definitions, dosage, patient population)
  • Specific limitations (e.g., “substantially free of…”, particle size, polymorph form, dissolution profile)

No claim text or bibliographic record for RS62435 appears in the provided context, so no compliant claim-level analysis can be generated.

Surviving subject matter (what is actually enforceable)

Enforceability depends on:

  • What is recited in the independent claims
  • How the dependent claims narrow the scope
  • Any amendments during examination or post-grant proceedings

No legal status documents, claim amendments, or prosecution history are present in the provided material.


How does RS62435 fit into the broader patent family?

A correct landscape analysis needs:

  • The priority application(s) and dates
  • The family’s WO/EP/US counterparts
  • Any intermediate continuations/divisionals
  • Whether the family covers multiple “layers” (compound, salt/form, dosage, method)

No priority data or family links are present in the provided material.


Serbia-specific landscape considerations

Patent enforceability and regulatory linkage in Serbia typically interact with:

  • the patent register (national validity)
  • the state of prior art filing dates
  • the scope of granted claims

A Serbia-focused landscape requires the RS62435 entry itself (granted claims and status).


Key Takeaways

  • A complete, accurate scope-and-claims analysis for Serbia patent RS62435 requires the RS62435 record content (title, assignee, priority, full granted claim set, and legal status).
  • The provided chat content contains no verifiable RS62435 bibliographic or claim text, so a compliant, evidence-based claim scope and landscape impact cannot be produced.

FAQs

  1. What documents are required to analyze RS62435’s claim scope accurately?
    The granted claim set, bibliographic data (publication number, assignee, priority), and legal status (in-force/lapsed/revoked).

  2. How do independent claims drive enforcement in Serbia?
    Enforcement hinges on what the independent claims recite; dependent claims narrow scope and can define additional limitations.

  3. What role does the patent family play in Serbia landscape mapping?
    It determines whether earlier compound coverage or later-life-cycle filings (salt/polymorph/formulation/dosing) exist and whether they overlap in Serbia.

  4. Can landscape analysis be done without claim text?
    Not at the level of actionable scope, because category (composition vs use vs method), definitions, and limitations must be verified.

  5. How is RS62435’s enforceability assessed?
    By the granted claims’ status in the Serbian system and any proceedings that affect validity.


References

[1] (No cited sources are available because RS62435 bibliographic and claim data were not provided in the chat.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.